Background {#Sec1}
==========

Aging, which is broadly defined as the time-dependent functional decline that affects most living organisms, has attracted curiosity and excited imagination throughout the history of humankind \[[@CR1]\]. Nowadays, aging is known as a physiological process encompassing several body changes at macroscopic and microscopic levels throughout an organism's lifespan. Heart, brain, and muscle are considered as the most efficient model systems or tissues with the ability to affect aging and lifespan \[[@CR2]--[@CR5]\]. Through the study of various age-related diseases, such as Alzheimer's disease, hypertension, and Parkinson's disease, links between these age-related diseases and these model systems have been established \[[@CR6], [@CR7]\]. There are several factors, such as genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication, involved in the progression of aging \[[@CR1], [@CR2]\]. Nevertheless, due to the complexity of the molecular mechanisms involved in aging, we have not yet fully explained the causes, processes, and relationships between them.

Many previous studies have revealed differences between older and younger species at both the biological and molecular levels \[[@CR1]\]. A large mountof evidence indicates that tumor necrosis factor α (TNF-α), a Transforming growth factor (TGF)-secreted factor superfamily member, and ubiquitination and ubiquitin-like family proteins may play critical roles in the progression of aging \[[@CR8]--[@CR10]\]. Some differentially expressed genes involved in the process of aging have been revealed by microarray-based whole-genome gene expression analyses \[[@CR11]\]. A comprehensive and in-depth study of proteomics will help us to better understand the mechanism of aging.

Tissue-based quantitative clinical proteomics has emerged as an unbiased discovery tool to study the mechanisms of various diseases \[[@CR12]\]. Although many targeted investigations of aging have been designed to examine specific pathways that are significant to this phenomenon \[[@CR13], [@CR14]\], few studies have focused on the expression landscape of overall proteins in plasma, especially for human and monkey. However, plasma, an important component of the blood which has the central and integrating role in human physiology, can reflect the physical condition of an individual \[[@CR15]\]. For mice, some systemic factors in plasma can affect cognitive function, either positively by promoting neurogenesis, or negatively by reducing neurogenesis \[[@CR16]--[@CR19]\]. Therefore, we compared the differentially expressed proteins in plasma between young and aged subjects using iTRAQ-based quantitative proteomics to gain information to understand the mechanism of aging at the protein level.

Results {#Sec2}
=======

Characteristics of the clinical study {#Sec3}
-------------------------------------

We collected plasma samples from eight humans and eight monkeys. The human and monkey samples were equally divided into four different groups based on their age. There was a significant difference in age between the young and the aged. (*p* \< 0.05). Table [1](#Tab1){ref-type="table"} shows the detailed information of the samples. Table 1Characteristics of aged and young samples in this studyHumanMonkeyAgedYoung*P* valueAgedYoung*P* valueHealth StatusHealthHealth/HealthHealth/Age (year), mean (SD)87.25, 9.28726.25, 2.986\< 0.000121.75, 4.4257.5, 1.2910.0008Female86.00, 8.48521.5, 6.364/0.8446/0.9348Male88.50, 13.4422.0, 4.243

iTRAQ quantification of plasma protein profiles {#Sec4}
-----------------------------------------------

We employed iTRAQ labeling technology in combination with LC-MS/MS to investigate differentially expressed proteins in circulating blood between the aged and young groups. In total, 485 and 708 proteins were identified to be commonly expressed in human and monkey samples, respectively (Fig. [1](#Fig1){ref-type="fig"}a and Additional file [1](#MOESM1){ref-type="media"}: Figure S1A). These proteins were subjected to further analysis. Among the 485 identified human proteins, approximately 98% were more than 10 kDa (Fig. [1](#Fig1){ref-type="fig"}b). Approximately 95% of peptides were between 6 and 24 amino acid residues in length (Fig. [1](#Fig1){ref-type="fig"}c). Of the identified proteins, more than 62% had sequence coverage above 10% (Fig. [1](#Fig1){ref-type="fig"}d). More than 88% of the proteins contain less than 10 peptides, and the number of proteins decreases with the increase in the number of matching peptides (Fig. [1](#Fig1){ref-type="fig"}e). Fig. 1The human plasma proteome dataset from iTRAQ shotgun analysis. (**a**) A statistical chart for identifying basic information. Total spectra is the total number of secondary spectra, Spectra is the number of matched spectra, Unique Spectra is the number of matched peptides, Peptide is the number of peptides identified, Unique Peptide is the number of specific peptide sequences, and Protein is the number of proteins identified. (**b**) Mass distribution map of proteins based on molecular weight (kDa). (**c**) Distribution of different peptide length. (**d**) Distribution of peptide sequence coverage. (**e**) The quantitative distribution of identified peptides. (**f**) Quantity statistics of differential proteins

For monkey samples, among the 708 identified proteins, approximately 98% were more than 10 kDa (Additional file [1](#MOESM1){ref-type="media"}: Figure S1B). Approximately 96% of peptides were between 6 and 24 amino acid residues in length (Additional file [1](#MOESM1){ref-type="media"}: Figure S1C). Of the identified proteins, more than 44% had sequence coverage above 10% (Additional file [1](#MOESM1){ref-type="media"}: Figure S1D). More than 90% of the proteins contain less than 10 peptides, and the number of proteins decreases with the increase in the number of matching peptides (Additional file [1](#MOESM1){ref-type="media"}: Figure S1E).

The subcellular localizations, molecular functions, and biological processes of identified proteins were analyzed by GO annotation. For human samples, extracellular region (14.18%), cell part (13.83%), cell (13.83%) and organelle (10.08%) were the most representative cell component classifications among the identified proteins (Fig. [2](#Fig2){ref-type="fig"}a). In terms of molecular functions, the most representative groups of the identified proteins were binding (48.46%), catalytic activity (20.79%), and enzyme regulator activity (9.08%) (Fig. [2](#Fig2){ref-type="fig"}b). In biological processes,single-organism process (9.64%), cellular process (8.94%), biological regulation (8.24%), response to stimuli (8.21%), metabolic process (8.1%) were the most representative of the processes (Fig. [2](#Fig2){ref-type="fig"}c). Fig. 2Gene ontology (GO) annotation and functional classification of identified serum proteins from all human samples. GO terms for cellular compartment (**a**), molecular function (**b**), and biological process (**c**)

In monkey samples, cell part (15.52%), cell (15.52%), organelle (12.29%) and extracellular region (9.33%) were the most representative cell component classifications among the identified proteins (Additional file [2](#MOESM2){ref-type="media"}: Figure S2A). In terms of molecular functions, the most representative groups of the identified proteins were binding (47.72%), catalytic activity (21.16%), structural molecule activity (8.25%) and enzyme regulator activity (7.69%) (Additional file [2](#MOESM2){ref-type="media"}: Figure S2B). In biological processes, cellular process (9.71%) single-organism process (9.56%), metabolic process (8.49%), biological regulation (7.86%), regulation of biological process (7.34%) and response to stimuli (7.23%) were the most representative of the processes (Additional file [2](#MOESM2){ref-type="media"}: Figure S2C).

Differential levels of plasma proteins between aged and young samples {#Sec5}
---------------------------------------------------------------------

For the human samples, of the 485 identified proteins, 38 were up-regulated (ratio Aged/Young ≥1.3, *p* \< 0.05) and 36 were down-regulated (ratio Aged/Young ≤0.667, *p* \< 0.05) (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}). For the monkey samples, of the 708 identified proteins, 51 were up-regulated (ratio Aged/Young ≥1.3, *p* \< 0.05) and 18 were down-regulated (ratio Aged/Young ≤0.667, *p* \< 0.05) (Additional file [3](#MOESM3){ref-type="media"}: Table S1 and Additional file [4](#MOESM4){ref-type="media"}: Table S2). Although the similarity of the differentially expressed proteins in humans and monkeys was not high, we found only IGFBP4 protein that existed in up-regulated proteins in aged both for human and monkey. Then it was focused for subsequent analysis. Table 2Up-regulated proteins, identified in aged of humanNumberAccessionProtein symbolDescriptionGene symbolMean ± SDE_Value1Q15113PCOC1Procollagen C-endopeptidase enhancer 1PCOLCE1.92 ± 0.5302P05090APODApolipoprotein DAPOD1.58 ± 0.31.00E-953Q9UHG3PCYOXPrenylcysteine oxidase 1PCYOX1.58 ± 0.5104P03950ANGIAngiogeninANG1.49 ± 0.411.00E-735O76076WISP2WNT1-inducible-signaling pathway protein 2WISP21.89 ± 0.625.00E-896P00450CERUCeruloplasminCER1.28 ± 0.3407P0CG05LAC2Ig lambda-2 chain C regionsIgG LC1.34 ± 0.285.00E-548P07988PSPBPulmonary surfactant-associated protein BSFTPB1.44 ± 0.4209Q86UD1OAFOut at first protein homologOAF1.47 ± 0.41.00E-14110Q9HDC9APMAPAdipocyte plasma membrane-associated proteinAPMAP1.7 ± 0.83011P05160F13BCoagulation factor XIII B chainF13B1.46 ± 0.5012P27918PROPProperdinCFP2.53 ± 0.27013P06727APOA4Apolipoprotein A-IVAPOA1.64 ± 0.36014P02745C1QAComplement C1q subcomponent subunit AC1QA1.23 ± 0.247.00E-12615P22692IBP4Insulin-like growth factor-binding protein 4IGFBP41.51 ± 0.334.00E-12616P07357CO8AComplement component C8 alpha chainC8A1.79 ± 0.23017O00187MASP2Mannan-binding lectin serine protease 2MASP22.69 ± 0.98018P02749APOHBeta-2-glycoprotein 1APOH1.32 ± 0.262.00E-10819Q9NZP8C1RLComplement C1r subcomponent-like proteinC1RL2.07 ± 0.18020P48740MASP1Mannan-binding lectin serine protease 1MASP12.57 ± 0.99021P05164PERMMyeloperoxidaseMPO2.24 ± 0.82022Q15485FCN2Ficolin-2FCN22.52 ± 0.656.00E-15823P26927HGFLHepatocyte growth factor-like proteinMST11.51 ± 0.42024P01876IGHA1Ig alpha-1 chain C regionDKFZp686K181961.85 ± 0.9025P02788TRFLLactotransferrinLTF3.3 ± 1.16026P07360CO8GComplement component C8 gamma chainC8G1.4 ± 0.152.00E-10327P36980FHR2Complement factor H-related protein 2CFHR24.84 ± 1.313.00E-13728P02743SAMPSerum amyloid P-componentAPCS2.1 ± 0.234.00E-12929Q03591FHR1Complement factor H-related protein 1CFHR12.41 ± 0.55030Q99969RARR2Retinoic acid receptor responder protein 2RARRES21.43 ± 0.254.00E-9131P01859IGHG2Ig gamma-2 chain C regionDKFZp686I041961.9 ± 0.922.00E-18032Q96KN2CNDP1Beta-Ala-His dipeptidaseCNDP11.36 ± 0.15033P01764HV303Ig heavy chain V-III region VH26VH32.28 ± 1.044.00E-4034Q03591FHR1Complement factor H-related protein 1FHR-13.66 ± 2.088.00E-1535O00602FCN1Ficolin-1FCN12.81 ± 0.92036Q16769QPCTGlutaminyl-peptide cyclotransferaseQPCT1.82 ± 0.73037P61628LYSCLysozyme CLYZ3.61 ± 1.212.00E-8238P48740MASP1Mannan-binding lectin serine protease 1DKFZp686M05621.88 ± 0.496.00E-51 Table 3Down-regulated proteins, identified in aged of humanNumberAccessionprotein symbolDescriptiongene symbolMean ± SDE_Value1Q76FE5H2BHistone H2BABCF20.31 ± 0.16.00E-282Q13201MMRN1Multimerin-1MMRN10.77 ± 0.1803P08571CD14Monocyte differentiation antigen CD14CD140.48 ± 0.0404P13796PLSLPlastin-2HEL-S-370.19 ± 0.0805P05556ITB1Integrin beta-1ITGB10.42 ± 0.0306P02776PLF4Platelet factor 4PF40.48 ± 0.172.00E-407Q6Q788APOA5Apolipoprotein A-VAPOA50.75 ± 0.1408Q96PD5PGRP2N-acetylmuramoyl-L-alanine amidasePGLYRP20.46 ± 0.1409P08697A2APAlpha-2-antiplasminSERPINF20.51 ± 0.13010Q9UK55ZPIProtein Z-dependent protease inhibitorSERPINA100.38 ± 0.1011P19823ITIH2Inter-alpha-trypsin inhibitor heavy chain H2ITIH20.65 ± 0.08012P02760\|AMBPProtein AMBPAMBP0.38 ± 0.09013Q96KK5H2A1HHistone H2A type 1-HHIST1H2AG0.49 ± 0.072.00E-5414P04275VWFvon Willebrand factorVWF0.48 ± 0.08015P12111CO6A3Collagen alpha-3(VI) chainCOL6A30.43 ± 0.09016Q9UGM5FETUBFetuin-BFETUB0.24 ± 0.04017P15169CBPNCarboxypeptidase N catalytic chainCPN10.71 ± 0.12018P22792CPN2Carboxypeptidase N subunit 2CPN20.7 ± 0.2019Q5XIF6TBA4ATubulin alpha-4A chainTUBA4A0.83 ± 0.18020P29622KAINKallistatinSERPINA40.2 ± 0.07021P05452TETNTetranectinCLEC3B0.43 ± 0.024.00E-11622P35858ALSInsulin-like growth factor-binding protein complex acid labile subunitIGFALS0.58 ± 0.14023P04196HRGHistidine-rich glycoproteinHRG1.76 ± 0.63024Q13790APOFApolipoprotein FAPOF1.40 ± 0.43025P55058PLTPPhospholipid transfer proteinPLTP1.39 ± 0.11026P04070PROCVitamin K-dependent protein CLOC1.87 ± 0.642.00E-3527P01764HV303Ig heavy chain V-III region VH26IGHV3--491.32 ± 0.245.00E-4228O95445APOMApolipoprotein MAPOM1.40 ± 0.252.00E-11029P06702S10A9Protein S100-A9S1003.10 ± 1.596.00E-6230Q5R1X3ACTBActin, cytoplasmic 1LOC2.23 ± 0.62031P05543THBGThyroxine-binding globulinSERPINA72.26 ± 0.56032P04278SHBGSex hormone-binding globulinSHBG3.77 ± 0.144.00E-17133P10720PF4VPlatelet factor 4 variantPF4V11.35 ± 0.316.00E-3334P00748FA12Coagulation factor XIIF121.69 ± 0.70035P36955PEDFPigment epithelium-derived factorSERPINF11.45 ± 0.26036P19827ITIH1Inter-alpha-trypsin inhibitor heavy chain H1ITIH12.16 ± 0.160

KEGG pathway analysis of differentially expressed proteins {#Sec6}
----------------------------------------------------------

In human aged samples, differentially expressed plasma proteins were mainly enriched in three pathways, while in young plasma samples, differentially expressed plasma proteins were mainly enriched in seven pathways by KEGG pathway analysis. These included Pathogenic *Escherichia coli* infection, ECM-receptor interaction, Phagosome, Focal adhesion, PI3K-Akt signaling pathway and PPAR signaling pathway (Fig. [3](#Fig3){ref-type="fig"}). Fig. 3KEGG pathway analysis of differentially expressed proteins in human samples. (**a**) Significant differential genes enriched pathways in young samples. (**b**) Significant differential genes enriched pathways in aged samples

Validation of iTRAQ results in individual subjects {#Sec7}
--------------------------------------------------

To confirm the accuracy of our iTRAQ results, a key component that triggers senescence in young MSC \[[@CR20]\], IGFBP4, was selected for further study. Consistent with the results of the data in the Table [2](#Tab2){ref-type="table"} and Additional file [3](#MOESM3){ref-type="media"}: Table S1, the protein level of IGFBP4 was significantly up-regulated in the aged group compared with the young group (Fig. [4](#Fig4){ref-type="fig"}). Fig. 4Expression levels of IGFBP4 revealed by western blotting. (**a**) Coomassie blue staining of total protein loading; (**b**) Western blot analysis of IGFBP4 in human young and aged plasma

IGFBP4 impaired cognitive performance of mice {#Sec8}
---------------------------------------------

It is well recognized that aging can be accompanied by cognitive impairment. To evaluate the effects of IGFBP4 on cognitive performance, through tail vein injection at a does of 2.67 μg/kg, once every other day over the course of 1 month, into mice with 8 months ages, 13 mices were divided into two groups: Control group (*n* = 6) and IGFBP4 group (*n* = 7), we examined mice in the Morris water maze. During the test time, there was no significant difference between the two groups in swimming speed (Fig. [5](#Fig5){ref-type="fig"}a). Although there was no significant difference between the two groups, the duration time in the quadrant where the platform was previously placed that the IGFBP4 group spent was less than the control group (Fig. [5](#Fig5){ref-type="fig"}b). Meanwhile, compared with the control group, the mice of the IGFBP4 group also significantly reduced the number of times they crossed over the previous position of the platform (Fig. [5](#Fig5){ref-type="fig"}c). Moreover, the IGFBP4 group showed a significant increase in the time getting to the stage for the first time compared with the control group (Fig. [5](#Fig5){ref-type="fig"}d). These results demonstrated that IGFBP4 could aggravate the dysfunction of cognitive ability in mice. Fig. 5Morris water maze analysis of behavior of 8 months mice injected with IGFBP4 protein. (**a**) The swimming speed of the two groups of mice. (**b**) The time spent in the target quadrant of the two groups of mice (*p*=0.1314 ). (**c**) Number of times the two groups of mice crossed the platform (\**p*\< 0.05). (**d**) The time of the two groups of mice first appeared on the platform (\*\**p*\<0.01)

Discussions {#Sec9}
===========

Aging is a phenomenon that results from a complex interaction of diverse factors. The mechanisms underlying aging are very intricate and many factors such as aging cells and tissue remodeling, telomeres, DNA repair, growth, energy homeostasis, and reproductive function have been implicated in the process of aging \[[@CR1]\]. Although many factors related to aging have been identified, the overall mechanism of aging is highly complicated, so specific causes of aging are still unclear. Proteins circulating in the blood are critical for aging; however, the serum proteome from human and monkey has remained largely unexplored. Therefore, studies at the proteome level would help us to better understand the changes in the mechanisms associated with aging.

In our study, 74 proteins and 69 proteins were identified differentially expressed in aged plasma compared with young plasma in human and monkey samples, respectively. Through GO annotation analysis, it was revealed that most of the significant proteins in aging belong to cell parts, extracellular region, and organelle, and mainly participate in the cellular process, metabolic process, and single-organism process. It was revealed that phagosome, complement and coagulation cascades, primary immunodeficiency, dilated cardiomyopathy, and viral myocarditis pathways are the main signaling pathways activated in aging via KEGG pathway analysis, indicating that cardiovascular diseases and inflammatory responses may play a significant role in the process of aging.

Association between IGFBPs and aging {#Sec10}
------------------------------------

Insulin-like growth factor I (IGFI) and IGFII are members of the insulin superfamily of growth-promoting peptides and are among the most abundant and ubiquitous polypeptide growth factors. The IGFs are distinguished from insulin by their interaction in circulating blood and the cellular environment with six high-affinity IGF binding proteins (IGFBPs) that have multiple functional properties \[[@CR21]\]. In addition to altering the equilibrium between the IGFs and their cell-surface receptors, the IGFBPs can also regulate signaling what is stimulated by other growth factors through their distinct receptors \[[@CR21]\].

Almost all members of IGFBP family, such as IGFBP1/2/3/4/5, are involved in coordinately regulating growth within the physiological context of changing metabolic demands \[[@CR22]\]. Several studies have identified that IGFBPs can affect biological responses by interacting with cell-surface proteins \[[@CR22]\]. IGFBP1 and 2 can modulate cell migration and adhesion by binding to α5β1 integrin \[[@CR23], [@CR24]\]. IGFBP2 induces activation of the PI3 kinase/AKT pathway through indirect action by binding to a cell-surface receptor termed receptor tyrosine phosphatase beta (RPTPβ) \[[@CR25], [@CR26]\]. In addition, IGFBPs are involved in insulin resistance, lipid metabolism, diabetes,carbohydrate metabolism, bone metabolism, and atherosclerosis \[[@CR22], [@CR27]--[@CR30]\].

As a member of IGFBP family, IGFBP4 mainly mediates the cellular signaling by banding to IGF1 that can limit the amount of free IGF in extracellular fluid that is available for receptor activation \[[@CR22]\]. IGFBP4 can act as an inhibitor of the canonical Wnt signaling required for cardiogenesis and provides a molecular link between IGF signaling and Wnt signaling \[[@CR31]\]. There is evidence that IGFBP4 expression increases with age and is associated with the impairment of MSC differentiation via the Erk and Smad pathway \[[@CR32]\]. Consistent with previous studies that indicated IGFBP4 as a key component needed for triggering senescence in young MSC and a harmful factor that impair the habituation learning, which is correlated with cognitive function \[[@CR20], [@CR33]\], our present study demonstrated that IGFBP4 was up-regulated in the plasma of aged compared with young subjects and that injection of IGFBP4 into mice also accelerates cognitive dysfunction. IGFBP4 also plays a critical role in adipogenesis and loss of IGFBP4 can induce a decrease in adipose tissue \[[@CR34]\].

Association between proteolytic systems and aging {#Sec11}
-------------------------------------------------

There is growing evidence that normal and pathological aging are often associated with impaired protein homeostasis or proteostasis \[[@CR35]\]. Both mechanisms are involved in restoring the structure of misfolded polypeptides and in their removal and degradation, thus preventing the accumulation of damaged components and ensuring the continuous renewal of intracellular proteins \[[@CR36], [@CR37]\]. The function of these systems plays a vital role in the survival of cells. Additionally, the accumulation of unfolded, misfolded, or non-degraded proteins is a major factor in the development of some age-related pathologies, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease \[[@CR38]\]. Moreover, it has been demonstrated that the activities of the ubiquitin-proteasome system and the autophagy-lysosomal system, which are the two principal proteolytic systems implicated in protein quality control, decrease with aging \[[@CR38], [@CR39]\], supporting the view that impaired proteostasis constitutes a common feature of old age.

Regarding autophagy, a double transgenic mouse model in which the amount of the lysosomal receptor for chaperone-mediated autophagy (CMA, one type of autophagy), does not result in an age-dependent decrease in autophagic activity and preserves improved hepatic function with aging \[[@CR40]\]. Also, rapamycin, which is an inhibitor of the mTOR pathway, can induce macroautophagy (another form of autophagy different from CMA) to extend median and maximal lifespan of mice \[[@CR41], [@CR42]\]. Notably, it had been reported that rapamycin delays multiple aspects of aging in mice \[[@CR43]\].

Consistent with the relevance of proteolytic systems in the process of aging, our present study also revealed that the Phagosome pathway plays a key role in the biology of aging. However, although its influence is not obvious in our study, another pathway, Fc gamma receptor-mediated phagocytosis, is also involved in the process. Therefore, all of the above indicate that aging is involved in perturbed proteostasis, and that experimental perturbation of proteostasis can precipitate age-associated pathologies \[[@CR1]\].

Association between inflammation and aging {#Sec12}
------------------------------------------

In recent years a lot of previous researches found that aging also involves changes at the level of endocrine, neuroendocrine or neuronal intercellular communication \[[@CR44]--[@CR47]\]. Consistent with these results, our present study revealed involvement of Complement and coagulation cascades and Primary immunodeficiency pathway in aging at the protein level. Although the exact mechanism underling aging is still unknown, a prominent aging-associated alteration in intercellular communication, termed "inflammaging" has been widely accepted as a hallmark associated with aging \[[@CR48], [@CR49]\]. Inflammaging may result from multiple causes, such as genetic susceptibility, visceral obesity, microbiota and gut permeability, cellular senescence, impaired recycling and elimination of degraded cellular material, or intrinsic defects in immune cells and chronic infections \[[@CR8]\]. Inflammation is also associated with the pathogenesis of obesity and type 2 diabetes, two conditions that contribute to and correlate with aging in the human population \[[@CR50]\]. Similarly, defective inflammatory responses play a critical role in atherosclerosis \[[@CR51]\]. At the same time, modulating inflammaging as a promising strategy to slow the decline of health that occurs with aging has become more and more widely accepted \[[@CR8]\]. Thus, it is reasonable to conclude that pathways related to inflammation play a crucial role in the biology of aging.

Conclusions {#Sec13}
===========

In summary, due to the extremely large dynamic range of plasma proteins and some inherent defects of the iTRAQ \[[@CR52], [@CR53]\], we did not identify many specific proteins related to aging compered with other subjects \[[@CR52], [@CR54]\]. Our results yet revealed that the differentially expressed IGFBP4 between aged and young samples is related to the process of aging. In addition,our present study indicated that proteolytic systems and inflammatory responses may play a significant role in the process of aging. Thus, our study suggested a possible relationship between some growth factors, such as IGFBPs, proteolytic systems, and inflammatory responses can affect the process of body aging.. This may provide novel insight into the prevention of aging.

Methods {#Sec14}
=======

Animals {#Sec15}
-------

The mice used in the experiment were all C57BL/6, purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. Mice were maintained on a 12 h light/dark schedule, and allowed free access to food and water, following protocols approved by the Animal Research Committee of Tongji Hospital, Tongji University School of Medicine, China. After the test of Morris water maze, the mice were anesthetized with tribromoethanol (Sigma, Saint Louis, USA), then the mice were killed by cervical dislocation.

Sample collection and protein extraction {#Sec16}
----------------------------------------

For LC-ESI-MS/MS, plasma samples from eight humans and eight *Macaca fascicularis* monkeys were collected and divided into four groups: Aged-Human (H), Young-H, Aged-Monkey (M) and Young-M. The plasma sample from each individual was stored at − 80 °C for further testing.

To reduce the complexity of samples, the highly abundant proteins were depleted using ProteoMinerTM Kits (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacturer's protocol. The smaples was added to a mixture of protein lysate, 1 mM PMSF, and 2 mM EDTA. 5 minters later, adding 10 mM DTT. After 15 min of ultrasonic lysis, then centrifuged at 25,000×g for 20 min. The supernatant was added 5 times volume of precooled acetone and precipitated at − 20 °C for 2 h, then centrifuged for 20 min with 16,000×g. Follow the previous steps for another precipitation cracking. Then the supernatant was treated with 10 mM DTT for 1 h at 56 °C, followed by adding 55 mM IAM in a dark room for 45 min. Next, appropriate amount of cold acetone was add to the sample, incubating at − 20 °C for 2 h. After centrifugation of 25,000×g for 20 min, the precipitation was dissolved in 200 uL 0.5 M TEAB for 15 min of ultrasonic lysis, followed by another centrifugation of 25,000×g for 20 min. The protein concentration of each sample was determined by using the BCA Kit (Sango Bioteh, Shanghai, China).

iTRAQ labeling {#Sec17}
--------------

Proteins (100 μg) were digested with trypsin (protein:trypsin = 20:1; Sigma) and incubated at 37 °C for 4 h. More trypsin was then added at the above proportion and incubation continued at 37 °C for 8 h. The peptides were then dried with a vacuum centrifugal pump and 0.5 M TEAB was used to resolubilize the peptides. Peptides were then labeled with iTRAQ with incubation at room temperature for 2 h according to the manufacturer's instructions. The labeled peptides were mixed and separated on an SCX column through the LC-20AB liquid phase system (Shimadzu, Kyoto, JPN).

LC-ESI-MS/MS analysis based on TripleTOF 5600 {#Sec18}
---------------------------------------------

Each component was redissolved to about 0.5 μg/μl in buffer A (5% ACN, 0.1% FA) and centrifuged for 10 min to remove insoluble matter. Five-microliter samples of each component (about 2.5 μg protein) were separated by the LC-20 AD system (Shimadzu, Kyoto Japan). The separation procedure was as follows: first, the sample was transferred to the Trap column over 4 min at a flow rate of 8 μL/min. An analytical gradient with a total flow rate of 300 μL/min was then added to bring the sample into the column. Then the sample was separated and transferred to the mass spectrometry system. Elution was performed under 5% buffer B (95% ACN, 0.1% FA) for 5 min, followed by a linear gradient for 35 min in which the proportion of buffer B increased from 5 to 35%. The proportion was then increased to 60% for the next 5 min, then increased to 80% over 2 min where it remained for 2 min. Finally the proportion of buffer B was recovered to 5% over 1 min and balanced for 10 min. The machine used was a TripleTOF 5600 (AB SCIEX, Concord, ON) with a Nanospray IIIsource (AB SCIEX, Concord, ON) ion source and a quartz radiator (New Objectives, Woburn, MA).

Bioinformatics analysis {#Sec19}
-----------------------

The database was used in this study: Uniprot_homo (127497sequences), link address: (<http://www.uniprot.org/uniprot/?query=taxonomy:9606>). The Software Mascot was used to identify protein, version Mascot2.3.02. It has been rated as the gold standard of biological mass spectrometry software by Frost/Sullivan research institutions. Gene Ontology (GO) database (<http://www.geneontology.org>.) was used to classified the functional annotation of proteins into 3 categories: biological process, molecular function, and cellular component. The significant enrichment analysis of GO function was performed to identify GO terms that were significantly enriched in differentially expressed proteins. When the protein abundance ratio was more than 1.5 times and its *p*-value was less than 0.05, the protein was regarded as the differential protein between different samples. The significant enrichment analysis of Pathway is based on KEGG Pathway to find out the significant enrichment of Pathway in differential proteins compared with all the identified protein backgrounds.

Western blotting {#Sec20}
----------------

To validate the accuracy of iTRAQ results, western blot analysis was performed.

The plasma was diluted ten times by PBS. 30 μL of samples per lane were loaded for 10% Bis-Tris polyacrylamide gels and then transferred onto PVDF membrane (Millipore, Billerica, MA) by electroblotting. The membranes were blocked in TBS 0.5% Tween containing 5% skim milk powder (OXOID, Basingstoke, UK) for 1 h at room temperature and incubated with primary antibody: anti-IGFBP4 (Abcam, Cambridge, UK) overnight at 4 °C. Then the membranes were incubated with peroxidase-conjugated secondary antibodie (Bio-Rad, Hercules, USA) for 1 h at room temperature. The bands were visualized by using Millipore's enhanced chemiluminescence (ECL) with the Amersham Imager 600 detection system (GE, Boston, USA). The western blot results represent at least 2 independent biological replicates.

Behavioral test {#Sec21}
---------------

Spatial learning and cognitive flexibility were evaluated using a Morris water maze (WMW) \[[@CR55], [@CR56]\], which consisted of a circular pool (150 cm in diameter), filling with water maintained at room temperature (23 ± 1 °C), opacified by adding nontoxic white. The platform (diameter in 15 cm) was hidden 1 cm underneath the water surface in the middle of one fixed quadrant ('target') of the pool. Four different colors and dimensions visual cues were attached to the side of the pool equidistant from one another, and the pool was surrounded by a plain curtain to block any other visual cues. For training (day 1--5), mice were released randomly with their heads facing the pool wall from one of the four starting locations, and trained daily in four sequential sessions (15--30 min interval). Once mice were not able to locate the platform after 60 s, they were manually placed on the platform and allowed to remain on it for 20 s. For probe test (day 6), a 60 s probe trial was performed to assess the memory of the mice. The latency to locate the platform and velocity were recorded by EthoVision video tracking equipment and software (Noldus, Wageningen, The Netherlands).

Statistical analysis {#Sec22}
--------------------

The data are reported as the means ± SD, and statistical analysis between two groups was assessed using independent-samples t-tests or Mann-Whitney U tests. *p* \< 0.05 was considered statistically significant. All the statistical analyses were performed using SPSS software, version 22 (IBM, Armonk, USA) and GraphPad Prism, version 7 (GraphPad Software Inc.,San Diego, USA).

Supplementary information
=========================

 {#Sec23}

**Additional file 1: Figure S1.** Extended monkey plasma proteome dataset from iTRAQ shotgun analysis. **Additional file 2: Figure S2.** Gene ontology (GO) annotation and functional classification of identified plasma proteins from all monkey samples. GO terms for cellular compartment (A), molecular function (B), and biological process (C). **Additional file 3: Table S1.** Up-regulated proteins in aging of monkey. **Additional file 4: Table S2.** Down-regulated proteins in aging of monkey.

DAVID

:   Database for Annotation, Visualization and Integrated Discovery2

GO

:   Gene Ontology

iTRAQ

:   isobaric tags for relative and absolute quantification

TNF-α

:   tumor necrosis factor α
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